Nationwide cost and benefit was estimated for performing computed tomography (CT) on headache patients in the hope of discovering a specific finding, subarachnoid hemorrhage. Case finding costs were estimated using a previously published survey of CT use at a university hospital where, of 258 headache patients scanned , two had subarachnoid bleeding due to ruptured aneurysms. The incidence and natural history of ruptured aneurysms from a large-scale clinical trial and the outcome of surgery from the recent literature were used in the calculations. The results ranged from a worst case calculation of $24,713 / year and $543,688 / person saved (ignoring all other diagnoses) to a best case calculation of $1 ,999 / year and $43,975 / person assuming that other positive dia9noses were of equal outcome to ruptured aneurysms. The analysis, using a technique recommended as a model for future determinations of this type, also demonstrated that a most important variable in determining costs is the case finding rate. If there is a need to improve the use of new diagnostic technologies, such as CT, concentration should be on the identification of the characteristics of high-yield patient groups.
In 1944, Dandy [1] published a monograph describing his surgical approach to ruptured intracranial aneurysms. By the late 1950s, surgery for ruptured aneurysms had become a com mon but controvers ial procedure. In 1960, McKissock et al. [2] reported on the results of 599 ruptured aneurysms and concluded that, with the exception of intracranial hematomas, surgery provided no increase in survival compared with conservative treatment (i .e., bed rest, sedatives, seizure precautions , etc.). As recently as 1974, the results of a large multicentered trial also questioned the value of direct surgical treatment [3] .
In more recent years, improved surgi cal techniques combined with studies identifying low-risk patients and optimum timing of operation have increased enthusiasm for surgery. For selected patients, an aggressive operative approach is now widely followed that produces significant reductions in morbidity and mortality [4] [5] [6] [7] [8] . However, because of the long-standing controversy over surgery, a number of large scale clinical trials have compared conservative and medical approaches [9, 10] . As a result, substantial information now exists on the incidence and natural history of subarachnoid hemorrhages of all causes, including those associated with ruptured aneu rysms.
We know that the annual incidence of subarachnoid hemorrhage is 16 / 100,000 (about 33,600 / year in the USA [6] ). About 54% (18 ,144) of these are secondary to a ruptured arterial aneurysm . Without treatment , 40% of aneurysm patients have recurrent bleeding within 8 weeks and 60% of these second hemorrhag es are fatal. An aneurysm patient who survives the initial rupture and is treated conservatively has a 50% chance of surviving for 1 year [9, 10] . Therefore, the chief advantage of surgery is that it offers the pati ent definitive protection from a recurrent hemorrhage and its attendant risk of death or severe disability.
Another finding from these therapeutic trials is that one of th e most important [4] [5] [6] [7] [8] .
In describing initial signs and symptoms, most authors use the c lassification of Botterell et al. [11] or the more recent modification of Hunt and Hess [7] . These c lassification systems rank patients from grade 1 (headache) to grade 5 (coma) (table 1). About 20% of patients are first seen in grade 1; the rest are divided about equally in the other four grades. If untreated, 89 % of grade 1 patients will progress to grades 2-5 within 1 year [10] .
There is seldom much difficulty clinically detecting grades 2-5. However, grade 1 patients are a diagnostic problem.
In the past, a patient complaining of a sudden severe headac he but without other symptoms or signs was either treated for headache or hospitalized for observation and possible lumbar puncture .
The introduction of computed tomography (CT) increased the diagnostic choices . Extravasated blood is easily recognized by CT and the location of the ruptured aneurysm may occasionally be predicted by its distribution into the subarachno id space and adjo ining brain [12 , 13] . One study recommended the substitution of CT for lumbar puncture in possible ruptured aneurysm patients [14] .
About 12 million visits to physicians each year are by patients complaining of headaches [15] . Whether or not to scan a headache patient is ultimately a c lini cal decision, based on th e experience and best judgment of the examining physic ian. In many cases , the examining physician can rely on the history alone as evidence against a serious underlying disease. In others , a limited neurologic examination may give enough reassurance . However, the timing , c haract er , history, and physical ex amination are not always definitive, and the physici an must decide if CT is indicated .
With increasing economic pressure , how can physicians , economists , and oth er social observers determine th e economic effects of physici ans ' actions? What are the economic c onsequences of using CT in patients with severe headache? How do th e c osts and benefits compare? Where c ould improvements be made?
Materials and Methods
We previ ously revi ewed th e recent experiences of physicians referrin g pati ents for CT scanning at Georg e Washington Un iversity Hospital (GWUH) [16] . Th e results of our survey showed th at wh en 258 headache pati ents were scanned, 2 0 clinica lly important di- (table 2) . Since a great deal of information existed on both the natural history and results of treatment of ruptured aneurysms, we decided to use our diagnostic yie lds and the current results with surgery to ca lculate the cost and benefits of scanning patients with headache in search of persons with subarachnoid bleeding due to aneurysms. The method used to find the diagnostic yields is described in detail elsewhere [16] . Briefly, during a 1 year study period at GWUH , all requests for CT scanning were prospectively placed in diagnostic categories according to the most specific initial sign or symptom . After scanning , a diagnostic yield (number of positive scans / total number of scans ordered) was computed for each category using a list of preselected positive clinically important CT findings.
During the study period there was no attempt to limit access to the scanner. Referrals for CT head scanning came from neurologists, neurosurgeons, internists , general surgeons, and si x other specialty groups on a first come , first served basis. With the exception of. scans obtained on an emergency basis, prior approval by an attending neurologist was unnecessary. We believe this open access policy is largely standard throughout the USA.
To complete th is cost-benefit study, th e 42 patients diagnosed by CT as having subarachnoid hemorrhage were followed for actual short-term outcome. In 3 6 of these (all but the si x patients with stroke), a ruptured an eurysm was actually confirmed by angiography; 3 4 were initially seen in grades 2-5.
Results
Using these diagnostic yields and the 1977 average nationwide cost for CT study of $255 ($190 technical cost , $65 professional fee) [17], case finding costs for subarachnoid hemorrhage were then calculated at $32,895 for grade 1 patients and at $1 ,050 for grades 2-5. (Overhead and indirect costs are not considered in subsequent discussion .) These individual case finding costs were used to determine total nationwide CT scanning costs assuming two separate decisions (figs. 1-3). Decision 1 assumes that all patients with severe headaches will be scanned and that the diagnostic yield of scanning headache patients at GWUH is replicated nationwide. Decision 2 assumes that no patients with headache alone will be scanned and requires a second neurologic sign and / or symptom before a scan is ordered. Using these two decisions, the incremental costs of scanning headache patients were determined . Th is determination was based on nationwide annual incidence figures and the natural history of bleed ing due to ruptured aneurysms. The net incremental cost of scanning 468,258 headache patients to find the 3 ,629 bleeding aneurysm patients was $115,984 ,450 (table 3 ) .
The total number of headache pati ents scanned under both decisions is based on diagnostic yield ; th at is , if two bleed ing patients are found for every 258 patients scanned , then to detect the 3,629 (20% of 18,144) total grade 1 patients each year, 468,2 58 patients must be scanned. As is discussed later, small changes in the diagnostic yield can • Assumes that 89% o f grade 1 pa ti ent s det eriorat e to a lower grad e over 1 yea r. t Inc ludes surgical deaths and patients inca pable of self-ca re.
produce substantial differences in total costs and in the final cost-benefit calculation.
To determine what th is $116 million provides in terms of improved morbidity and mortality, outcomes were calculated for decisions 1 and 2 . Figures 1 and 2 describe dec ision 1 , in which all grades 1-5 patients are scanned . Figure 3 traces the outcomes under dec ision 2, in which only grades 2-5 patients are accepted for scanning.
We derived most of our 1 year outcomes and grades of patients at surgery from five recent large-scale studies of bleeding aneurysm patients that used comparable pati ent classification systems . These studies are summarized in table 4, and the outcomes in figures 1-3 combined these studies with the known natural history of ruptured aneurysm .
Because of the better operative results with grades 1 and 2 pati ents, there are 215 fewer total deaths under decision 1. This benefit is achieved by performing 1,308 more operations on grade 1 patients and 937 fewer high-risk ope rations on grades 3 and 4 patients. If we use the 1977 average nationwid e charge and professional fee for arteriography, craniotomy , and 3 weeks hospitalization of $7,500 for the additional c raniotomies and a total charge of $9 ,500 for the high-risk operations (an increase of $2,000 to account for 20 more hospital days), the net increase in surg ical costs is $908 ,500 . Total incremental costs for decision 1 versus dec isio n 2 become $116,892,950.
KNA US ET AL. t Gross c osts adjusted for th e reduced amount of scannin g among grades 2-5 patient s and the increased c osts of added surgery and hospitalization.
To better describe the total benefit, we know that whi le bleeding aneurysms occur from the late teens to age 70, the peak incidence occurs around the fifth to sixth decades [9, 10] . Life insurance mortality tables predict that a male or female who lives to be 55 will have 22 more years of life [18] (this assumes that the patients will not die from other cerebral aneurysms, polycystic kidney disease, or aortic coarctation). Therefore, by following decision 1, 215 individuals and 4 ,730 years of life are saved . At a total cost of $116,892 ,950, this means each year of life saved costs $24,713 and each person $543,688 (table 5) .
Limits on Analysis
Our worst case calculation used a number of simplifying assumptions. Two of the most important were that CT scanning represents perfect information (i.e ., no false-positive or -negative scans) and that if the patient does not have a subarachnoid bleeding, no other disease is present.
The effect of this latter assumption, that we are only screening headache patients for bleeding, has the effect of underestimating benefits relative to costs. Subarachnoid hemorrhage is obviously only one of many potential diagnoses physicians considered when referring headache patients for CT, and the characteristics of patients referred with a sudden severe headac he separate them from other more chronic sufferers. Indeed, there were 18 other positive CT diagnoses made on the 258 headache pati ents. To be complete, each one of them should be separately analyzed for the expected results from tests done after CT as well as further treatment. The same is true for patients referred because of a presumptive diagnosis of su barac hnoid hemorrhage who actually had other diseases. However, the number of possible outcomes combined with the difficulty of finding comparable and accurate outcome data for each diagnosis makes this calcu lation inaccessible.
One way of estimatin g the potential impact of th is limitation is to calcu late the cost-benefit ratio using the assumption that all 20 positive diagnoses obtained among the 258 headache patients had a response to medical therapy and outcome simi lar to bleeding aneurysms . We call this a best case calculation since few, if any, of the other diagnoses possib le in headache patients (tumors, hydrocephalus, abscess) respond to therapy as well as ruptured aneurysms. As seen in table 5, the results of this best case calculation substantiall y lower the case finding cost and improve the cost-benefit ratio by a factor of 10. Because of the exponential nature of the cost-benefit curve, the costs become less pronounced as more cases are detected .
The sensitivity and specificity of CT can also be estimated . Using a high false-negative rate estimate for CT detection of subarachnoid bleeding of 10% (as suggested by two studies that looked at all grades of bleeding patients [12, 14] ), the effect on the final cost-benefit conclusion is as follows. Assuming that the symptoms of grades 2-5 patients will prompt the diagnosis to be pursued regardless of the CT results, the effect of the false-negative rate is that 363 grade 1 ruptured aneurysm patients each year will be missed by CT. Eighty-nine percent or 323 will deteriorate during the year to grades 2-5 [10] .
The effect of these delayed diagnoses is 22 more deaths will occur under decision 1 . This increases the cost-benefit ratio to $27,530 / year or $605 ,663 / person saved. Thus, if the false-negative error rate remains at the 10% level, the cost per life saved increases by about 11 % across all case finding rates .
To date, there are not any reports of a false-positive CT diagnosis of subarachnoid bleed ing . Although it is unlikely this type of error will become a significant problem, its potential effect on our calculation can also be determined . If we assume a 10% false-positive rate , then every year under decision 1, 46,463 headache patients would have a false-positive CT scan indicating bleed ing . Then, if each of these cases were hospitalized and underwent lumbar puncture, it would add about $10.5 million to total costs. This would make the final cost-benefit calculation $592,525 / life saved. Of course, if false-positive results lead to hospitalization and angiography, not only would the total cost be increased but a small increase in mortality from angiography miQht also occur, further increasing cost per life.
In addition to the effects of other diseases and test errors, this calculation also does not consider the unknown cost of radiation exposure and the immeasurable but immense benefit of a true-negative finding to the patient concerned and frightened over the possibility of disease. This latter point is important to both clinicians and health planners . Since good medical practice includes reassuring patients concerning the absence of disease, the value of a truenegative test, although not expl ic itly stated, must be understood and considered implicitly when reviewing cost-benefit calculations. This calcu lation also assumes that the patient classification used by different observers is the same, that the observations on incidence and prevention are accurate, and that persons successfully treated for bleeding aneurysm will have a mortality equal to the general population.
Finally, it is important to return to the most important limitation of this study: the reliability of the case finding rate among grade 1 patients. The number of bleeding aneurysm cases found in our study, two, is not large enough to be viewed as a precise estimate of the exact incidence among patients with headaches. As is well known by clinicians, the character of a headache frequently associated with subarachnoid bleeding is sudden and severe, often characterized as "the most severe headache possible." The diagnostic yield of headache patients meeting this criteria should be substantially higher than two of 258. Because of this it may be more realistic to use the best case calculation of 20 / 258 as approximating the case finding rate, $43,975 as the cost / life saved, and $1,999 as the cost / year saved.
Discussion
Is life priceless? If it is, then our calculations are pointless. However, if there is a limit, an amount so great that we question whether a medical action is appropriate in a certain situation, then cost-benefit calculations can be useful. Although costs will never be the sole determinant in medical decisions, they can be incorporated into decision making .
How we view our best case estimate of $1 ,999 / year of life saved depends on how it compares with other decisions. In a nationwide comparison of coronary care units, mobile coronary care units, and costs for cholesterol screening and education, Cretin [19] estimated that it costs from $269 (screening) to $3,141 (mobile coronary care units) to save 1 year of life from heart attacks.
Collen [20] found the cost of diagnosis under different schedules of physical examinations and mammography screening to vary from $12 ,480 / cancer patient for a group unscreened previously to $18,193 / cancer patient for clinical examinations and screening mammograms. The potential benefit of these various decisions was not estimated .
Compared with the $3,141 estimate of Cretin [19] , $1 ,999 seems a small price for 1 more year of life. This benefit is even more pronounced since the natural history and prognosis of patients with their first myocardial infarction is substantially worse than that of patients with successfully treated ruptured aneurysms, in whom reoccurrence is low. It is difficult to compare our results directly with the Collen [20] breast cancer study because benefits were not estimated. However, his case finding costs, ($12,480-$18,193) are substantially higher than ours.
The large influence of the case finding costs on the final cost-benefit calculation is another striking conclusion from our study. Substantial c hanges in specificity and sensitivity of scanning, shifts between low-and high-risk surgery, and length of hospitalization do not greatly alter the final costbenefit figure. But, as demonstrated in table 5, increasing the diagnostic yield by a small percentage (e.g., finding three bleeding aneurysm patients for every 258 patients scanned instead of two) can substantially reduce costs. Likewise a similar reduction of only one bleeding aneurysm patient doubles the cost per year of life saved. Because of the importance of the diagnostic yields to the final calculation it would be desirable to obtain a larger data set from other institutions on which to base these calculations. A similar survey reported from Peter Bent Brigham Hospital revealed no positive CT scans in 53 headache patients [21 ] .
Assuming such diagnostic yields, major advances in the efficiency of CT scanning can best be achieved by better defining patient groups likely to benefit from its use before ordering the test. This is particularly true for patients with a less than 5% probability of positive results . Such improvements are likely to be much more effective at reducing costs than efforts aimed at improving use by patients declared abnormal once tested .
